Compile Data Set for Download or QSAR
Report error Found 81 Enz. Inhib. hit(s) with all data for entry = 50016224
TargetTyrosine-protein kinase JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 2.10nMAssay Description:Inhibition of human recombinant GST-tagged JAK1 catalytic domain (866 to 1154 residues) expressed in baculovirus expression system by Z'-lyte assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 8nMAssay Description:Inhibition of JAK1/TYK2 signaling pathway in human primary T-cells assessed as reduction of IFN-alpha induced STAT1 phosphorylationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593316(CHEMBL5170161)
Affinity DataIC50: 9nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593315(CHEMBL5209379)
Affinity DataIC50: 9nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593304(CHEMBL5191312)
Affinity DataIC50: 11nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 12nMAssay Description:Inhibition of human recombinant GST-tagged JAK2 catalytic domain (809 to 1153 residues) expressed in baculovirus expression system by Z'-lyte assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 12nMAssay Description:Inhibition of human recombinant N-terminal GST-tagged TYK2 (833 to 1187 residues) expressed in baculovirus expression system by Z'-lyte assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593318(CHEMBL5187209)
Affinity DataIC50: 12nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593289(CHEMBL5178640)
Affinity DataIC50: 17nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593305(CHEMBL5186181)
Affinity DataIC50: 18nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 20nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593308(CHEMBL5205935)
Affinity DataIC50: 20nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 20nMAssay Description:Inhibition of JAK1/JAK3 signaling pathway in human primary T-cells assessed as reduction of IL-2 induced cell proliferationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593311(CHEMBL5198389)
Affinity DataIC50: 21nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593309(CHEMBL5207437)
Affinity DataIC50: 22nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593303(CHEMBL5175645)
Affinity DataIC50: 23nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593317(CHEMBL5184050)
Affinity DataIC50: 23nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593310(CHEMBL5192889)
Affinity DataIC50: 26nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593302(CHEMBL5204721)
Affinity DataIC50: 32nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593288(CHEMBL5204815)
Affinity DataIC50: 34nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593291(CHEMBL5169819)
Affinity DataIC50: 34nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593319(CHEMBL5188333)
Affinity DataIC50: 37nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593312(CHEMBL5173045)
Affinity DataIC50: 37nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593313(CHEMBL5192063)
Affinity DataIC50: 38nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593318(CHEMBL5187209)
Affinity DataIC50: 42nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593306(CHEMBL5179746)
Affinity DataIC50: 51nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593314(CHEMBL5203646)
Affinity DataIC50: 58nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593307(CHEMBL5194652)
Affinity DataIC50: 64nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593294(CHEMBL5189275)
Affinity DataIC50: 65nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593295(CHEMBL5201990)
Affinity DataIC50: 69nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593296(CHEMBL5190167)
Affinity DataIC50: 77nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593298(CHEMBL5196240)
Affinity DataIC50: 80nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593310(CHEMBL5192889)
Affinity DataIC50: 81nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593308(CHEMBL5205935)
Affinity DataIC50: 84nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593292(CHEMBL5183029)
Affinity DataIC50: 91nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593293(CHEMBL5199794)
Affinity DataIC50: 92nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593290(CHEMBL5208935)
Affinity DataIC50: 106nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593297(CHEMBL5192620)
Affinity DataIC50: 116nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593301(CHEMBL5204045)
Affinity DataIC50: 119nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593311(CHEMBL5198389)
Affinity DataIC50: 132nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593316(CHEMBL5170161)
Affinity DataIC50: 170nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593315(CHEMBL5209379)
Affinity DataIC50: 173nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593299(CHEMBL5179252)
Affinity DataIC50: 237nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593317(CHEMBL5184050)
Affinity DataIC50: 354nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetCytochrome P450 3A4(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593313(CHEMBL5192063)
Affinity DataIC50: 400nMAssay Description:Inhibition of CYP3A4 (unknown origin) in presence of NADPHMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK1/JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 417nMAssay Description:Inhibition of JAK1/JAK2 signaling pathway in human U-937 cells assessed as reduction of IFN-gamma induced ICAM1 expressionMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetJAK3/JAK1(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 451nMAssay Description:Inhibition of JAK1/JAK3 signaling pathway in human whole blood assessed as reduction of IL-2 induced STAT5 phosphorylationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593320(IFIDANCITINIB | Ifidancitinib | Ati-502 | A-301 | ...)
Affinity DataIC50: 490nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetCytochrome P450 3A4(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593312(CHEMBL5173045)
Affinity DataIC50: 500nMAssay Description:Inhibition of CYP3A4 (unknown origin) in presence of NADPHMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Rigel Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50593314(CHEMBL5203646)
Affinity DataIC50: 503nMAssay Description:Inhibition of JAK2 signaling pathway in human CHEP cells assessed as inhibition of EPO-induced cell survival preincubated for 1 hr followed by EPO ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
Displayed 1 to 50 (of 81 total ) | Next | Last >>
Jump to: